trial · primary record
Telisotuzumab Adizutecan
Non Small Cell Lung Carcinoma
| Phase | Phase 1, Phase 2 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 252 |
| Primary completion | 2027-11 |
| Primary endpoint | Part 1: Dose-Limiting Toxicities (DLT)s of Telisotuzumab Adizutecan |
| Registry ID | NCT06772623 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-28T02:33:07.148Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT06772623
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.